- Home
- VTMX vs IRON Comparison
VTMX vs IRON Comparison
Compare VTMX & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTMX
- IRON
- Stock Information
- Founded
- VTMX 1998
- IRON 2017
- Country
- VTMX Mexico
- IRON United States
- Employees
- VTMX N/A
- IRON N/A
- Industry
- VTMX
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- VTMX
- IRON Health Care
- Exchange
- VTMX Nasdaq
- IRON Nasdaq
- Market Cap
- VTMX 2.4B
- IRON 2.1B
- IPO Year
- VTMX 2023
- IRON N/A
- Fundamental
- Price
- VTMX $26.50
- IRON $62.63
- Analyst Decision
- VTMX Sell
- IRON Strong Buy
- Analyst Count
- VTMX 2
- IRON 10
- Target Price
- VTMX $29.50
- IRON $97.80
- AVG Volume (30 Days)
- VTMX 99.3K
- IRON 290.2K
- Earning Date
- VTMX 10-23-2025
- IRON 11-11-2025
- Dividend Yield
- VTMX 2.50%
- IRON N/A
- EPS Growth
- VTMX N/A
- IRON N/A
- EPS
- VTMX 0.04
- IRON N/A
- Revenue
- VTMX $263,061,301.00
- IRON N/A
- Revenue This Year
- VTMX $12.94
- IRON N/A
- Revenue Next Year
- VTMX $10.26
- IRON N/A
- P/E Ratio
- VTMX $68.73
- IRON N/A
- Revenue Growth
- VTMX 11.49
- IRON N/A
- 52 Week Low
- VTMX $21.30
- IRON $30.82
- 52 Week High
- VTMX $30.07
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- VTMX 34.19
- IRON 62.67
- Support Level
- VTMX $26.68
- IRON $59.65
- Resistance Level
- VTMX $27.31
- IRON $63.54
- Average True Range (ATR)
- VTMX 0.50
- IRON 2.48
- MACD
- VTMX -0.17
- IRON 0.04
- Stochastic Oscillator
- VTMX 15.15
- IRON 61.97
About VTMX Corporacion Inmobiliaria Vesta S.A.B de C.V. each representing ten (10)
Corporacion Inmobiliaria Vesta SAB de CV is an internally managed real estate company that owns, manages, develops, and leases industrial properties in Mexico. The Company's primary business is the acquisition, development, and management of industrial and distribution center real estate. The company designs and constructs park-to-suit projects across various industries; undertakes build-to-suit projects; and provides site selection, design and engineering, and sale and leaseback services. The primary source of revenue is the rental income received from customers under operating leases. It serves aerospace, automotive, food and beverage, logistics, medical devices, plastics, and other industries.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.